Pioneering the Next Generation
of Precision ADC Therapeutics
Ryan Corcoran, M.D., Ph.D.
Co-Founder & Director
About Sidewinder
Sidewinder Therapeutics is pioneering the next generation of bispecific antibody-drug conjugates.
We aim to deliver next-generation bispecific antibody-drug conjugates (ADCs) that expand the therapeutic window for patients with difficult to treat cancers. Built by a dynamic team of serial entrepreneurs, expert scientists and drug developers, we are advancing bispecific ADCs engineered to target receptor co-complexes that are highly expressed on certain solid tumors with enhanced tumor cell specificity and internalization.
Leadership Team
The Sidewinder Team has extensive experience in drug discovery and development and is committed to delivering therapies to improve the lives of patients.
Board of Directors
Daniel Estes, Ph.D.
Director
Carl Gordon, Ph.D., C.F.A.
Director
John Hamer, Ph.D.
Director
Eric Murphy, Ph.D.
Chief Executive Officer,
Co-Founder, & Director
Josh Richardson, M.D.
Director
Michal Silverberg
Director
Advisors
Morris Rosenberg, D.Sc
CMC Strategy and Management
Laurie Tatalick, Ph.D.
Non-Clinical & Toxicology
Valerie Odegard, Ph.D.
Scientific Advisor
Patrick A. Zweidler-McKay, M.D., Ph.D.
Chief Medical Officer
Our Investors
Eric Murphy, Ph.D.
/in Leadership TeamChief Executive Officer,
Co-Founder, & Director
Rob McRae
/in Leadership TeamPresident &
Chief Operating Officer
Michael Mueller
/in Leadership TeamGeneral Counsel